The usage of SGLT-2 inhibitors in the management of heart failure in rural Africa: mitigating the barriers to the optimal adoption of a novel, adjuvant therapeutic agent in the management of heart failure-Reference-Cited by-同舟云学术

The usage of SGLT-2 inhibitors in the management of heart failure in rural Africa: mitigating the barriers to the optimal adoption of a novel, adjuvant therapeutic agent in the management of heart failure

Published:2023-01 Issue: Volume:17 Page:
ISSN:1753-9447
Container-title:Therapeutic Advances in Cardiovascular Disease
language:en
Short-container-title:Therapeutic Advances in Cardiovascular Disease

Author:

Ashinze Patrick¹²³,Abdul-Rahman Toufik⁴^ORCID,Wireko Andrew Awuah⁵

Affiliation:

1. Saint Francis Catholic Hospital, Okpara Inland, Warri Catholic Diocesan Hospitals, Delta State, Nigeria

2. Faculty of Clinical Sciences, University of Ilorin, Ilorin, Kwara, Nigeria Academy of Public Health, West African

3. Institute of Public Health, Abuja, Nigeria Toufik’s World Medical Association, Sumy, Ukraine

4. Toufiks World Medical Association, Sumy, Ukraine Medical Institute, Sumy State University, Antonova 10, Sumy 40007, Ukraine

5. Toufik’s World Medical Association, Sumy, Ukraine Medical Institute, Sumy State University, Sumy, Ukraine

Publisher

SAGE Publications

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/17539447231202933

Reference5 articles.

1. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials

2. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials

3. Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors prescription Among Physicians in Saudi Arabia

4. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis

5. SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis